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Cellular activation of the 72 kDa type IV procollagenase/TIMP-2
complex. Members of the collagenase family of enzymes have been
implicated as central mediators of a number of both physiologic and
pathologic processes. The 72-kDa type IV collagenase is secreted as a
latent proenzyme, complexed with tissue inhibitor of metalloprotein-
ase-2 (TIMP-2). Like other members of the collagenase family, this
enzyme complex must be converted to a catalytically active form for
proteolytic remodeling of extracellular matrix to occur. In the current
study we demonstrate an inducible cell-mediated activation of the
72-kDa type IV procollagenase/TIMP-2 complex. Isolation of the 62
kDa activated enzyme/TIMP-2 complex from conditioned media of
concanavalin A treated WI-38 fibroblasts demonstrated that the cell
activated species was proteolytically active and amino terminal se-
quencing gave the sequence YNFF. This is identical to that of the 62
kDa species generated following organomercurial activation of purified
72-kDa type IV procollagenase/TIMP-2 complex. We have also isolated
biosynthetically 35S-labeled 72-kDa type IV procollagenase/TIMP-2
complex and used this to further study the cellular activation process.
In cell lines tested the activator was retained in the residual cell fraction
following lysis in the presence of 0.2% (wt/vol) Brij-35. Inhibitor studies
demonstrated that processing and activation of 72-kDa type IV procol-
lagenase/TIMP-2 complex by the residual fraction was inhibited by 5
mM ethylenediaminetetraacetic acid and 0.5 msi I, lO-phenanthroline
demonstrating a metal atom dependence. The species responsible for
activation could be partially recovered in soluble form with 0.5%
(vol/vol) Triton X-l00 and 0.25% (wt/vol) CHAPS but was not salt
extractable. This cellular activation process differs from that demon-
strated for interstitial collagenase in that it is not mediated by soluble
factors and is not plasminogen activator/plasmin dependent.
Members of the matrix metalloproteinase family are respon-
sible for much of the physiologic and pathologic turnover of the
various extracellular matrices found throughout the body [1—3].
The post-translational regulation of matrix metalloproteinase
activity is mediated at two levels. Each member of the family is
synthesized and secreted as a zymogen, and the loss of an 80-84
residue amino-terminal domain is associated with the appear-
ance of proteolytic activity. It is believed that an unpaired
cysteine within this amino-terminal domain is coordinated with
the zinc atom at the active site of the enzyme [4—6]. This
coordination can be broken by organomercurial treatment, or
by limited proteolysis, allowing conformational rearrangement,
attainment of enzyme activity and auto-proteolytic processing
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of the proenzyme domain to generate a stable active enzyme
species. Once activated these metalloproteinases can be inac-
tivated by specific inhibitors such as tissue inhibitor of metal-
loproteinase (TIMP-1)1 [7, 8] and TIMP-2 [9—11]. In the case of
the 72-kDa and 92-kDa type IV collagenases this negative
regulation is complicated by the fact that these two members of
the family are secreted as latent proenzymes complexed with
TIMP-2 [11] and TIMP-1 [12], respectively. The 72-kDa type IV
procollagenase/TIMP-2 complex can be activated in vitro by
exposure to organomercurial compounds to generate active
enzyme/TIMP-2 complexes [13]. It has been suggested that
these enzyme/inhibitor complexes function to stabilize the
proenzyme form, which otherwise undergoes spontaneous ac-
tivation and autodegradation [13]. This has lead to the identifi-
cation of a stabilization site on the proenzyme form of the
72-kDa type IV collagenase which preferentially binds TIMP-2
over TIMP-1 [14].
The activation of these metalloproteinase-inhibitor com-
plexes is therefore likely to be a key step in the overall
expression of type IV collagenase activity. However, little is
known about the cellular activation mechanism for any of the
matrix metalloproteinases. Recent studies have shown that
plasmin is capable of activating both purified interstitial procol-
lagenase and prostromelysin. Indeed mixed cultures of human
dermal fibroblasts and epidermal keratinocytes appear to acti-
vate both proenzymes in a plasminogen activator/plasmin de-
pendent manner [15, 16]. Stromelysin can act in concert with
plasmin to increase the specific activity of interstitial collage-
nase, apparently by limited proteolysis of the carboxyl-termi-
nus, however it does not appear that stromelysin alone can
activate the proenzyme [15, 17]. Neither plasmin nor stromel-
ysin effectively activate purified 72-kDa type IV procollagenase
and the activation of this metalloproteinase-inhibitor complex is
the subject of much current research [18].
We have recently reported the cellular processing of exoge-
nous purified 72-kDa type IV procollagenase/TIMP-2 complex
by phorbol ester treated HT-l080 human fibrosarcoma cells
[19]. This cellular mechanism results in amino-terminal cleav-
age, generating lower molecular weight species. Concanavalin
A treatment of human gingival fibroblasts also results in the
generation of a lower molecular weight form of 72-kDa type IV
collagenase, with a concomitant increase in type IV collagenase
activity [20]. In the current study we have purified the lowest
molecular weight form of the 72-kDa type IV collagenase
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generated following cellular activation by concanavalin A
treated human embryonic fibroblasts. This species was shown
to be proteolytically active and its amino terminal sequence was
identical to the 62 kDa activated form generated by organomer-
curial treatment. Purified radiolabeled 72-kDa type IV procol-
lagenase/TIMP-2 complex was isolated and used to characterize
the cellular mechanism responsible of the activation of this
metalloproteinase/inhibitor complex.
Methods
Cell culture
WI-38, human embryonic lung fibroblasts and HT-l080,
human fibrosarcoma cells were obtained from American Type
Culture Collection (Rockville, Maryland, USA), and grown in
Dulbecco's modified Eagle medium (DMEM) (Gibco Laborato-
ries, Grand Island, New York, USA), supplemented with 10%
(vol/vol) fetal bovine serum (Hyclone Laboratories, Logan,
Utah, USA) and 25 tg/ml Gentamycin (Gibco). DMEM supple-
mented with 0.1% (voilvol) ITS (Collaborative Research Inc.,
Bedford, Massachusetts, USA) and 25 sg/ml Gentamycin was
used for growth under serum-free conditions.
Biosynthetic labeling and affinity purWcation of the 72-kDa
type IV procollagenase/TIMP-2 complex
Confluent monolayers of WI-38 cells were cultured for 20
hours in serum-free DMEM containing 1 sg/ml cold methionine
and SO CiIml 35S-methionine (Amersham Corporation, Arling-
ton Heights, Illinois, USA). The medium was collected and the
72-kDa type IV procollagenase/TIMP-2 complex purified by
passage over a gelatin-sepharose (Sigma Chemical Company,
St. Louis, Missouri, USA) affinity column. The affinity resin
was washed extensively in 50 mivi Tris-HC1 pH 7.6 containing
0.5 M NaCI, 5 mrt CaCI2, and 0.02% (wt/vol) Brij-35, and the
bound complex eluted in the same buffer containing 10%
(voLfvoi) dimethyl sulfoxide. The radiolabeled complex was
immediately dialysed against 50 mtvi Tris-HCI pH 7.6 containing
0.2 M NaC1, 5 m CaCI2, and 0.02% (wt/vol) Brij-35 (collage-
nase buffer) and concentrated in a Centricon-lO microconcen-
trator (Amicon, Danvers, Massachusetts, USA).
The purified complex was stored at —70°C. Complex was also
purified from HT-1080 cells which synthesize and secrete the
gelatin-binding 92-kDa type IV procollagenase in addition to the
72-kDa proenzyme/TIMP-2. Aliquots of each complex were
analyzed by electrophoresis on 4 to 20% gradient or 14%
acrylamide gels (Novex, Encinitas, California, USA) in the
presence of SDS and processed for fluorography with Autofluor
(National Diagnostics, Manville, New Jersey, USA) according
to the manufacturer's instructions. Protein concentrations were
determined by Bio-Rad protein microassay (Bio-Rad Laborato-
ries, Richmond, California, USA).
Gelatin zymography
Secretion of both 92-kDa and 72-kDa type IV procollagenases
was followed by gelatin zymography [21] as adapted for a
minigel format [19]. Type IV procollagenases are dissociated
from TIMP's by the presence of SDS during electrophoresis.
Removal of SDS following electrophoresis allows the proen-
zymes to renature in an active or partially active conformation,
and permits their detection along with lower molecular weight
activated forms [22, 23]. Aliquots of conditioned media (S jd)
were mixed with sample buffer and applied directly, without
prior heating or reduction, to 10% acrylamide gels containing 1
mg/mi gelatin (Novex). The gels were run and processed as
previously described [19]. The gelatinolytic activity of each
collagenase was evident as a clear band against the blue
background of stained gelatin.
Cellular activation of biosynthetically labeled 72-kDa type IV
procollagenase/TIMP-2 complex
HT-1080 and WI-38 cells were grown to confluency and
treated with 12-O-tetradecanoylphorbol 13-acetate (TPA) (10
nglml) and concanavalin A (10 g/ml) under serum-free condi-
tions for 15 and 24 hours respectively. Following treatment,
conditioned media (10 ml/75 cm2) were removed and retained,
and a mild lysis buffer, consisting of 50 mi Tris-HC1 pH 7.6, 0.2
M NaC1, 5 mi CaC12, and 0.2% (wt/vol) Brij-35, was added (5
ml/75 cm2). Incubation was continued at 37°C for 15 minutes,
and the lysate and cell residue then separated by centrifugation
at 2,000 x g, for 30 minutes. The lysate was removed and
retained, and the cell residue resuspended in the same buffer
(0.5 ml/75 cm2 equivalent).
For the comparison the conditioned media and lysates were
concentrated 20- and 10-fold respectively in a Centricon-lO
microconcentrator. Aliquots (10 pi, 8 to 11,000 cpm) of purified
radiolabeled 72-kDa type IV procoilagenase/TIMP-2 complex
were added to varying amounts of conditioned medium, cell
lysate, and resuspended cell residue (10 to 40 pi) in a final
volume of 50 pi. and incubated at 37°C for 22 hours. Following
incubation, samples were centrifuged at 12,000 x g, for two
minutes. Aliquots of each reaction were analyzed by electro-
phoresis on 4 to 20% gradient or 14% acrylamide gels in the
presence of SDS and processed for fluorography with Autofluor
(National Diagnostics, Manville, New Jersey, USA) according
to the manufacturer's instructions.
Extraction of cell residue
Aliquots (40 p1) of cell residue were centrifuged at 12,000 x
g, for two minutes, and resuspended in the same buffer (40 p1),
without Brij-35, containing either 0.5 to 1.0% (vollvol) Triton
X-100 or 0.25 to 1.0% (wt/vol) CHAPS. After extraction for 15
minutes at 20°C, the samples were centrifuged at 12,000 x g, for
two minutes, and the extracted residue was resuspended in 40
p1 of buffer with 0.2% (wt/vol) Brij-35. Both extracted residue
and extract were incubated with radiolabelled complex as
before. Following incubation the samples were centrifuged and
the supernatant analyzed by SDS-PAGE/fluorography.
Gelatin degradation assay
Latent and active forms of type IV collagenase were purified
by gelatin sepharose affinity chromatography from untreated
and concanavalin A treated WI-38 conditioned medium respec-
tively. Aliquots of purified enzyme in collagenase buffer were
then treated with 1 m p-aminophenyl-mercuric acetate
(APMA) for 30 minutes at 37°C. Aliquots of untreated and
APMA treated enzyme were further diluted in collagenase
buffer and assayed for gelatinase activity. The radiolabeled
gelatin substrate was prepared by diluting 20 p1 (1.2 jsCi) of
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Fig. 1. Zymogram analysis of gelatinolytic activity in conditioned media. Conditioned media from WI-38 fibroblasts (A) and HT-1080
fibrosarcoma cells (B), cultured in the absence (0) and presence of concanavalin A (10 g/m1) for 24, 48, 72, and 96 hours, was subjected to
zymography as described. Medium was replaced after every 24 hour period. (C). Conditioned media from HT-1080 cells cultured in the presence
of TPA (10 ng/ml) (T) for 24 hours. Conditioned medium from WI-38 fibroblasts cultured in the presence of concanavalin A for 48 hours was run
for comparison (CA).
3H-type I collagen (1.0 mCi/mg; New England Nuclear, Wilm-
ington, Delaware, USA) with 480 d of 1 mg/ml cold type I
collagen in collagenase buffer. The substrate mix was then
heated at 55°C for 25 minutes and allowed to cool slowly to
room temperature. The final assay reaction contained 40 isl of
substrate and 140 sl of diluted enzyme. Samples were incu-
bated for 16 hours at 37°C, and the reaction then stopped by
addition of 20 p1 0.25 M ethylenediaminetetraacetic acid
(EDTA). Undigested gelatin was precipitated in all but the total
count control, by addition of 60 p110% trichloroacetic acid/5%
tannic acid. After chilling on ice for 10 minutes, samples were
centrifuged at 10,000 x g for 10 minutes and the supernatants
counted in triplicate.
Amino terminal sequence analysis
The latent and active forms of the 72-kDa type IV collagenase
were purified from untreated and concanavalin A treated fibro-
blasts by gelatin-sepharose affinity chromatography as de-
scribed. Samples of the purified preparations were run on 12%
polyacrylamide gels (Novex) and transferred to Immobilon
PDVF membranes using the Novex blot module. Transfer was
conducted in 10 mi 3-{cyclohexylamino}-1-propane-sulfonic
acid, pH 11/10% (vol/vol) methanol for two hours at 120 mA.
After transfer the membranes were washed extensively in
MilliQ water and stained with 0.1% (wt/vol) Coomassie Blue
R-250 in 50% methanol. After destaining in 50% methanolllO%
acetic acid, membranes were rinsed in MilliQ water, dried and
stored at —20°C. Amino terminal sequence analysis was per-
formed on selected bands cut from the PDVF membrane and
sequenced directly using a Porton Instruments 2020 gas-phase
sequenator as described previously [11].
Results
Concanavalin A treatment of WI-38 fibroblasts and HT-1 080
fibrosarcoma cells induces specific processing of the 72-kDa
type IV procollagenase
Analysis of WI-38 fibroblast conditioned medium by gelatin
zymography revealed only a single gelatinolytic species, iden-
tified as the 72-kDa type IV procollagenase (Fig. 1A) [19].
Treatment of these cells with concanavalin A (10 g/ml) in-
duced the cell-mediated conversion of the 72 kDa proenzyme to
a lower molecular weight species which is similar in molecular
weight (62 kDa) to that seen following organomercurial treat-
ment of purified 72-kDa type IV procollagenase/TIMP-2 com-
plex [5]. Conversion to this 62 kDa form was complete by 48
hours, and the stable production of this activated form contin-
ued over the subsequent 48 hours incubation (Fig. IA). This 62
kDa activated form was purified from conditioned medium by
gelatin-affinity chromatography and assayed for gelatinolytic
activity against soluble radiolabeled gelatin, with and without
prior treatment with 1 msi APMA. Organomercurial treated and
untreated preparations of this cellular activated form showed
similar specific activities (21.8 and 22.8 mg gelatin degraded/mg
enzyme/hr at 37°C). These specific activities are comparable to
that of the APMA treated preparation of purified latent 72-kDa
proenzyme/TIMP-2 complex (15.6 mg/mg/hr). Untreated com-
plex showed no detectable gelatinolytic activity.
Amino terminal sequence analysis of the 62 kDa activated
enzyme species obtained following gelatin-affinity chromatog-
raphy of concanavalin A treated WI-38 fibroblast conditioned
media gave an amino terminal sequence of YNFF. This se-
quence is identical to that previously obtained following orga-
nomercurial activation of affinity-purified 72-kDa type IV
procollagenase/TIMP-2 complex [24].
HT-1080 fibrosarcoma cells secrete both 92-kDa and 72-kDa
type IV procollagenases [12, 19]. Concanavalin A treatment of
HT-1080 cells induced similar changes in the processing of the
72 kDa proenzyme with the 62 kDa activated form being the
principal gelatinolytic species present following 48 hours of
treatment (Fig. IB). Secretion of the 92 kDa type IV procolla-
genase was reduced as a result of the concanavalin A treatment,
and there was no evidence of processing of the 92 kDa proen-
zyme to activated forms (Fig. lB). Phorbol ester treatment of
HT-1080 cells also induced the selective processing of the
72-kDa type IV procollagenase/TIMP-2 complex, although in
A
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this cell system an intermediate form of approximately 68 kDa
molecular weight is seen (Fig. 1 B and C).
The concanavalin A treatment of WI-38 fibroblasts and the
phorbol ester treatment of HT-1080 fibrosarcoma cells were
subsequently used as model systems for studying the specific
cell-mediated conversion of 72-kDa type IV procollagenase/
TIMP-2 complex to the 62 kDa activated form.
Processing of 72-kDa type IV procollagenase to a 62 kDa
activated form is confined to a residual cell fraction
Addition of purified radiolabeled 72-kDa type IV procollage-
nase/TIMP-2 complex to cultures of phorbol ester treated
HT-1080 cells demonstrated that these cells were able to
process exogenous proenzyme to lower molecular weight forms
[19]. Similar forms were seen following treatment of WI-38
fibroblasts with concanavalin A or purified latent complex with
APMA. To further define the location of processing activity in
the phorbol ester treated HT-1080 cells, and that in concanava-
un A treated WI-38 fibroblasts, radiolabeled complex was
incubated with cytosolic and residual cell fractions, and condi-
tioned media. The supernatants of these reactions were ana-
lyzed by SDS-PAGE and fluorography. This analysis of the
activation of exogenous, radiolabeled 72-kDa type IV procolla-
genase/TIMP-2 complex revealed that the processing activity in
both phorbol ester treated HT-1080 fibrosarcoma cells and
concanavalin A treated WI-38 fibroblasts was principally con-
fined to the cell residue (Fig. 2). The small degree of processing
by the highest concentration of each cell lysate did not generate
a specific 62 kDa form and is either the result of non-specific
protease activity or is due to the partial extraction of a small
amount of processing activity. Very little (< 5%) radiolabeled
complex was found to be associated with the insoluble cell
residue following incubation, suggesting that the association
during processing is transient. TIMP-2 was not appreciably
degraded during the cellular processing of the complex.
Demonstration of the processing of exogenous radiolabeled
proenzymetTlMP-2 complex by viable HT-1080 cells strongly
suggests an extracellular localization for this processing. That
the processing activity is confined to the residual cell fraction
and is not present in the conditioned medium further indicates
that the cellular processing and activation of this proenzyme/
inhibitor complex is a cell surface-associated event.
Cellular processing of 72-kDa type lv procollagenase/TIMP-2
complex is sensitive to metal ion chelators, but not serine
protease inhibitors
A plasminogen activator/plasmin cascade has been impli-
cated in the cellular processing and activation of both interstitial
collagenase and stromelysin [15, 16]. The processing of the
72-kDa type IV procollagenase/TIMP-2 complex by phorbol
ester treated HT-l080 cells and concanavalin A treated WI-38
fibroblasts was therefore tested for sensitivity to various pro-
tease inhibitors. Cell residues were prepared and incubated
with aliquots of radiolabeled complex as previously described.
Protease inhibitors were added to the cell residues 10 minutes
prior to the addition of radiolabeled complex. Analysis by
SDS-PAGE/fluorography demonstrated that processing was not
blocked by the serine protease inhibitors, phenylmethylsulfonyl
fluoride and aprotinin, or by the thiol protease inhibitor, leu-
peptin (Fig. 3 A—C). N-ethylmaleimide (0.5 to 5 mM) and the
aminopeptidase inhibitor, bestatin (5 to 25 LM), also failed to
—21
Fig. 2. Localization of cellular processing activity. Aliquots (10 pi. 8 to
10,000 cpm) of purified radiolabeled 72-kDa type IV procollagenase/
TIMP-2 complex were added to conditioned media (CM), cell lysates,
and cell residues from phorbol ester treated (10 nglml) HT-1080 cells (A)
and concanavalin A treated (10 g/ml) WI-38 fibroblasts (B) fraction-
ated in Situ with 0.2% (wtlvol) Brij-35. Following incubation at 37°C for
22 hours samples were centrifuged and the supernatants analyzed by
SDS-PAGE and fluorography as described. Values given are equivalent
volumes (pi) of each fraction used per assay.
block processing and activation (not shown). Processing to the
62 kDa form of the enzyme was, however, highly sensitive to
inhibition by metal ion chelators; 5 m'vi EDTA and 0.5 mM
1, lO-phenanthroline caused complete inhibition (Fig. 3B). Ad-
ditionally, processing activity was destroyed by heating the cell
residue at 90°C for five mm (not shown).
Concanavalin A and phorbol ester induced cellular process-
ing of endogenous 72-kDa type IV collagenasetrlMP-2 complex
was specific for this complex and did not affect the 92-kDa type
IV collagenase species (Fig. 1B). The specificity of processing,
as indicated by zymographic analysis, was confirmed by isola-
tion of radiolabeled 92-kDa type IV procollagenase and 72-kDa
type IV procollagenase/TIMP-2 complexes from HT-1080 cells.
Following incubation with cell residue, processing was ana-
lyzed by SDS-PAGE/fluorography as described. Residues from
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Fig. 3. Determination of sensitivity of cellular processing to protease
inhibitors. Aliquots (10 l, 8 to 10,000 cpm) of purified radiolabeled
72-kDa type IV procollagenase/TIMP-2 complex were added to cell
residues prepared from phorbol ester treated (10 ng/mI) HT-1080 cells,
and concanavalin A treated (10 gIm1) WI-38 fibroblasts. Additions of
inhibitors were made to cell residues, 10 minutes prior to addition of
complex. Following incubation at 37°C for 22 hours samples were
centrifuged and the supernatants analyzed by SDS-PAGE and fluorog-
raphy as described. (A) Incubation in the absence (CON) and presence
of phenylmethyl—sulfonyl fluoride (PMSF 1 mM) or ethylene-diamine-
tetraacetic acid (EDTA 20 mM). (B). Incubation in the absence (0) and
presence of 1 to 10 msi EDTA. (C) Incubation in the absence (0) and
presence of I ,10-phenanthroline (PH 0.5 mM), aprotinin (A 100 g/ml),
leupeptin (L 5 SM), or pepstatin (P 5 zM).
both concanavalin A treated WI-38 fibroblasts and phorbol
ester treated HT-1080 cells selectively processed the 72-kDa
proenzyme to the 62 kDa activated form; no processing of the
92 kDa proenzyme was detected (Fig. 4). This analysis of
radiolabeled complexes from HT-1080 also revealed an absence
of TIMP-1 in association with the 92 kDa enzyme as has
previously been reported [12].
Fig. 4. Specificity of cellular processing for the 72-kDa type IV procol-
lagenase. Aliquots (10 d, 8 to 10,000 cpm) of purified radiolabeled
72-kDa type IV procollagenase/TIMP-2 complex, isolated from HT-
1080 fibrosarcoma cells, were added to cell residues prepared from
phorbol ester treated (TPA) (10 nglml) HT-l080 cells, and concanavalin
A treated (CON A) (10 jgIml) WI-38 fibroblasts. Samples were incu-
bated in the absence (—) and presence (+) of EDTA at 37°C for 22
hours, and the supernatants analyzed by SDS-PAGE and fluorography
as described. A band corresponding to the 92-kDa type IV procollage-
nase is detected in these samples, however, no band corresponding to
TIMP-l was detected, even on longer exposures.
Processing activity recovered from the residual cell fraction
by detergent extraction
The solubility of the processing activity was examined by
extraction of the cell residue with Triton X-100 and CHAPS, a
zwitterionic detergent which has been reported to facilitate
extraction of proteins from membranes without loss of biolog-
ical activity 24]. Both concentrations of Triton X-l00 tested
removed all processing capacity from phorbol ester treated
HT-1080 cell residue, however, processing was not quantita-
tively recovered in the extract (Figs. 5 and 6). CHAPS was less
effective in extracting processing activity, but at a concentra-
tion of 0.25% (wt/vol) partial activity was recovered in the
extract, yielding both 68 kDa and 62 kDa forms. No activity was
detected in either Triton X-l00 or CHAPS extracts from con-
canavalin A treated WI-38 cell residues. The differences in
recovery of activity between the two cell lines is most probably
due to differences in the total amount of processing activity
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Fig. 5. Solubilily properties of the cellular processing activity. Cell
residues prepared from phorbol ester treated (10 ng/ml) HT-1080 cells
(A) and concanavalin A treated (10 g/ml) WI-38 fibroblasts (B) were
extracted with 0.5 to 1.0% (vol/vol) Triton X-l00 and 0.25 to 1.0%
(wt/vol) CHAPS. Aliquots (10 l, 8 to 10,000 cpm) of purified radiola-
beled 72-kDa type IV procollagenaselTlMP-2 complex were added to
extracted residues and extracts and incubated at 37°C for 22 hours.
Samples were then centrifuged and the supernatants analyzed by
SDS-PAGE and fluorography as described.
present. Concentrations of NaCI ranging from 0.15 to 1.5 M
failed to extract the processing activity from either cell residue
(not shown). These data suggest that the processing activity
may be membrane-associated, however, the recovery of this
processing activity from preparations of pure plasma mem-
branes has been difficult.
HT-1080 fibrosarcoma cells express a constitutive level of
processing activity
Zymographic analysis of HT-1080 conditioned medium indi-
cated that untreated HT-1080 cells process a small fraction of
their 72-kDa type IV procollagenaselTlMP-2 complex to yield
62 kDa activated forms [19]. This suggested that these cells
might exhibit a constitutive level of processing activity. Un-
Fig. 6. Determination of constitutive levels of processing activity.
Aliquots (10 p.l, 8 to 10,000 cpm) of purified radiolabeled 72-kDa type IV
procollagenase/TIMP-2 complex were added to cell residues prepared
from untreated (Control) and phorbol ester treated (TPA) (10 nglml)
HT-1080 cells (A), and untreated (Control) and concanavalin A treated
(CON A) (10 sg/ml) WI-38 fibroblasts (B). Cell residues were adjusted
to equal protein concentration prior to assay. Following incubation at
37°C for 2, 4, 6, and 8 hours samples were centrifuged and the
supernatants analyzed by SDS-PAGE and fluorography as described.
treated and treated, HT-l080 and WI-38 cells were therefore
fractionated by lysis in 0.2% (wt/vol) Brij-35 and the residual
cell fractions adjusted to give equal protein concentrations.
Fractions were assayed for processing activity as described.
Time course analysis over 2 to 10 hours revealed that both
untreated and phorbol ester treated HT-l080 cell residues
actively processed the radiolabeled complex to yield the 62 kDa
activated form of the enzyme (Fig. 6A). Analysis by quantita-
tive laser densitometry confirmed that the residue from phorbol
ester treated cells generated only slightly more of the 62 kDa
form of the enzyme than the residue from untreated cells. By
contrast, a marked difference was noted between the proportion
of the 62 kDa form from cell residues of untreated and con-
canavalin A treated fibroblasts (Fig. 6B). Residues from un-
treated WI-38 fibroblasts exhibited relatively little processing to
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the 62 kDa active enzyme consistent with the absence of
processed and activated forms as analyzed by zymography of
conditioned media. These results indicate that HT-l080 cells
possess a constitutive level of processing activity not found in
WI-38 fibroblasts.
Discussion
Our understanding of the activation of matrix metalloprotei-
nases is principally through in vitro studies of purified enzymes
using organomercurials, trypsin or plasmin as the activating
agent. A plasmin-mediated cellular mechanism for the activa-
tion of interstitial procollagenase and prostromelysin has been
reported [15]. However, very little is known about cellular
mechanisms for the activation of the type IV procollagenase/
TIMP complexes [18]. Zymographic analysis has shown that
low molecular weight active forms of the 72-kDa type IV
procollagenase can be induced in certain cell lines following
cytokine or phorbol ester treatment, and the cellular processing
of exogenous purified 72-kDa type IV procollagenase/TIMP-2
complex was demonstrated in such a system [19]. We have now
analyzed this cellular processing further and have sought to
determine whether it occurs in the conditioned medium or at the
cell surface, and whether it also is mediated by serine proteases
such as plasmin.
Zymogram analysis of conditioned media samples from con-
canavalin A treated and untreated WI-38 fibroblasts demon-
strated that the processing of endogenous 72-kDa type IV
procollagenase to a lower molecular weight form could be
induced but did not occur in unstimulated fibroblasts. Further-
more, isolation of the 72-kDa type IV procollagenase from this
cell line demonstrated that like previously characterized human
cells, such as A2058 melanoma cells or HT-1080 fibrosarcoma
cells, the proenzyme secreted by WI-38 fibroblasts was found
complexed with TIMP-2. This complex was subsequently la-
beled biosynthetically using 35S-methionine, purified by gelatin
affinity chromatography and used to further study this cellular
activation process.
Isolation of the 62-kDa activated type IV collagenase/TIMP-2
complex from conditioned media by gelatin-affinity chromatog-
raphy also demonstrated that this enzyme species was fully
proteolytically active. Following isolation of the 62 kDa spe-
cies, treatment with APMA did not enhance the specific activity
of this enzyme preparation with respect to its ability to degrade
soluble gelatin. In addition, the specific activity of the enzyme
complex generated by WI-38 cell activation was equivalent to
or slightly greater than that obtained following APMA activa-
tion of 72-kDa type IV procollagenase/TIMP-2 complex. Fi-
nally, direct amino acid sequencing of the 62-kDa type IV
collagenase following WI-38 cellular processing demonstrated
that the amino terminus of this enzyme is identical to that which
we have previously obtained for the APMA activated species
[5]. These data suggest that the cellular processing of the
72-kDa type IV procollagenase/TIMP-2 complex results in an
active enzyme species that is very similar if not identical to that
seen following organomercurial treatment of isolated, purified
72-kDa type IV procollagenase/TIMP-2 complex [5]. These
results differ from what we have previously reported on the
cellular processing of the 72-kDa type IV procollagenase/
TIMP-2 complex [19]. In the previous studies we identified a
processed form with an apparent molecular weight of 59 kDa
and an intermediate processed form in HT-l080 cell conditioned
medium with an apparent molecular weight of 62 kDa. These
molecular weight assignments were based on mobility relative
to molecular weight standards, and not with in vitro processed
enzyme/inhibitor complex following organomercurial treat-
ment. The results of the present study are consistent with the
original findings with the exception of the molecular weight
assignments. The molecular weights assigned to the activated
form ot the type IV collagenase are based on direct amino
terminal sequence analysis as well as comparison with organo-
mercurial activated standards.
By the criteria examined in the current study the mechanisms
for the processing and activation of the 72-kDa type IV procol-
lagenase/TIMP-2 complex by HT-1080 fibrosarcoma cells and
WI-38 fibroblasts are identical. Both are specific for the 72-kDa
proenzyme complex, are cell surface-associated, and show
similar solubility properties. Both mechanisms exhibit a metal
atom dependency, and neither is sensitive to serine protease
inhibitors. That the same mechanism can be induced by two
different treatments in a tumorigenic and a non-tumorigenic cell
line suggests that it is a general mechanism employed by a
variety of cells.
Studies with both serine protease inhibitors and anti-uroki-
nase antibody have shown that a plasminogen activator/plasmin
cascade is probably responsible for the cellular processing and
activation of both interstitial procollagenase and prostromelysin
in co-cultures of human dermal fibroblasts and epidermal kera-
tinocytes [15]. The specific cellular processing and activation of
the 72-kDa type IV procollagenase/TIMP-2 complex is not
sensitive to serine protease inhibitors, indicating that it is not
plasmin-mediated. The inhibition of processing by low concen-
trations of 1, 10,-phenanthroline suggests that the mechanism is
dependent upon a metal atom that can be removed by chelating
agents. This result could be explained by the action of a sec-
ond metalloproteinase, possibly membrane-associated, which
cleaves and activates the 72 kDa proenzyme. This second
metalloproteinase is unlikely to be stromelysin since neither cell
line synthesizes this enzyme (unpublished results). Interstitial
collagenase is induced in phorbol ester-treated HT-l080 cells
but is undetectable in untreated cells [19], which express a
constitutive level of processing activity. Alternatively, a mem-
brane-associated receptor/binding protein with specificity for
the 72 kDa proenzyme could bind and induce a conformational
rearrangement in the proenzyme, allowing attainment of enzy-
matic activity. This in turn would permit the autoproteolytic
processing of the enzyme, a step known to be sensitive to the
presence of metal atom chelators [5]. Interestingly, addition of
purified TIMP-2 (100 ng/ml) also blocked processing (not
shown). TIMP-2 is also known to block the autoactivation of
the 72-kDa type IV procollagenase [10]. The nature of the two
agents, phorbol myristate acetate and concanavalin A, used to
induce processing and activation does not in itself contribute to
an understanding of the mechanism involved since each appears
to act in a very different way. Ongoing research is directed at
the isolation and identification of the molecular species respon-
sible for activation.
The cellular processing and activation of the 72-kDa type IV
procollagenase differs in another respect from that described for
interstitial procollagenase. In studies on the latter it was possi-
ble to substitute keratinocyte conditioned medium for the
fibroblasts and keratinocytes. Incubation of this medium with
plasminogen and proenzyme resulted in activation [15]. By
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contrast no processing activity was detected in conditioned
medium from either phorbol ester treated HT-1080 cells or
concanavalin A treated WI-38 fibroblasts. The processing and
activation of 72-kDa type IV procollagenase therefore appears
to be retained at the cell surface, a feature which is likely to
have important implications in vivo since it would allow migrat-
ing/invading cells to restrict the activation of locally produced
proenzyme/TIMP-2 complex to the area of the migration or
invasion boundary.
When analyzed using radiolabeled complex the constitutive
processing activity of untreated HT-1080 cells is comparable to
that of phorbol ester treated HT-1080 cells. However, zymo-
graphic analysis demonstrates the presence of substantially
higher levels of the 62 kDa processed form in the conditioned
medium from phorbol ester treated HT-1080 cells (Fig. 1B).
Previous studies have shown that untreated HT-1080 cells are
unable to process exogenous radiolabeled 72-kDa proenzyme/
TIMP-2 complex [19]. The phorbol ester treatment may, there-
fore, mobilize an existing intracellular pool of processing activ-
ity, thus allowing greater efficiency in processing the 72 kDa
proenzyme. This would be consistent with the ability of phorbol
ester to induce processing activity within 6 to 12 hours. The
action of concanavalin A on both cell lines was slower (24 to 48
hr) and is more consistent with the de novo synthesis of proteins
involved in processing activity.
Specific cellular processing and activation of the 72-kDa type
IV procollagenase is likely to constitute a key step in the
post-translational regulation of type IV collagenase activity.
This enzyme is widely expressed by cells in culture and is found
in various tissues in vivo. The cellular processing and activation
described would allow cells to selectively activate this member
of the matrix metalloproteinase family at the cell surface. This
activation need not, necessarily, be proteolytic in nature, and
might be mediated by specific binding proteins that could alter
proenzyme conformation and trigger activation. Further inves-
tigation of this processing mechanism, and the role of TIMP-2 in
the proenzyme complex, should lead to a better understanding
of the involvement of type IV collagenases in both physiologic
and pathologic matrix remodeling.
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